The Langman laboratory is dedicated to the study of genetic diseases of children that produce metabolic bone disease, kidney stones, or other subtle forms of kidney disease.
The Mineral Metabolism Lab is located at Manne Research Institute and is part of the Developmental Biology Program. Research interests include Fibroblast Growth Factor 23 (FGF-23) as a novel cardiac disease biomarker, as a marker of AKI pre-operatively, and in diseases of hypophosphatemia. Additional interests include novel markers of vascular disease, progression of chronic kidney disease, disorders of vitamin D metabolism, and kidney stone formation.
Specific research interests include:
Genetic and acquired bone diseases of infants, children, and adolescents, and the effects of bone-specific therapy for them;
The osteodystrophy of chronic kidney disease, as a systemic disorder of bone and the vasculature;
Kidney stone diseases, including the primary hyperoxalurias, Dent's disease, and disorders of the extracellular calcium-sensing receptor;
Serving as a resource for measurement of bone and mineral homeostatic factors and agents, such as FGF-23, OPG, RANKL, inflammatory cytokines, and many others.
Current Research Projects
Fibroblast Growth Factor-23 and Adverse Cardiac Structure
Fibroblast growth factor-23 (FGF23) is a biomarker for cardiovascular disease. Obesity may promote FGF23 production in the absence of chronic kidney disease. FGF23 may be an early marker of cardiac injury in obese but otherwise healthy African American adolescents.